BCAL Diagnostics has secured a seat on Genetic Signatures' board, though it is only part of what it asked for. At an Extraordinary General Meeting, shareholders voted to appoint Dr John Melki to the GSS board but rejected the other three resolutions BCAL had put forward.

The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia are now open.

Australia's life sciences sector has converged on the Gold Coast for what organiser AusBiotech describes as the event's biggest edition yet, and for the first time, the peak body is running its three flagship conferences as a single, connected program.

Investors and Australian life sciences company leaders met on the Gold Coast this week for AusBiotech Invest, a curated forum designed to strengthen engagement between life sciences companies and capital.

CSL has named Deborah Waterhouse, a British pharmaceutical executive who previously led GSK in Australia, as its next chief executive and managing director.

Telix Pharmaceuticals has reaffirmed that it will pass US$1 billion in revenue and other income this year. Its third-quarter sales were consistent with the previous quarter, and it is working through a US$1.65 billion merger.

BioNTech has opened its clinical-scale mRNA manufacturing and research facility at La Trobe University's Bundoora campus, nearly three years after it first announced the plan.

As Australia's Biggest Week in Biotech approaches, AusBiotech is celebrating four emerging companies that have joined its growing national community through AusBiotech Connect, a membership designed to support the next generation of biotechnology, medical technology and health technology innovators.

Eleven life sciences companies will spend three minutes each making their case to investors on the Gold Coast this month. They will have no slides to lean on.

Australian biotech science has never been stronger, but the conditions around it are shifting. US drug pricing, China's rise and a rethink of American research funding are changing where medicines are discovered, developed and financed.

Tofflon Science and Technology Group will show a scale model of a modular CAR-T manufacturing facility at AusBiotech International 2026 on the Gold Coast.

Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.

Perth-based regenerative medicine company Orthocell says its nerve repair device could open a new market in prostate cancer surgery.

The PALACROS research program was formally launched in Amsterdam this week. It brings together leading European hospitals, researchers, patient organisations, and industry partners to improve treatment for patients with locally advanced pancreatic cancer.

Argent BioPharma has recast itself as an immune science company. In an update to shareholders, it said it will now focus its resources and research on inflammatory disease after licensing CannEpil to a global partner.

NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.

A new generation of Australian life sciences innovation will take the stage on the Gold Coast this month, with AusBiotech announcing the 2026 participants in its Early-Stage Innovation Forum.

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.

AusBiotech says the Government's R&D tax bill still penalises the clinical trial and manufacturing companies Australia most wants to keep. The industry body is now pushing for changes in the Senate.